Literature DB >> 2880656

Hypercalcemia and osteoclast proliferation in adult T-cell leukemia.

T Kiyokawa, K Yamaguchi, M Takeya, K Takahashi, T Watanabe, T Matsumoto, S Y Lee, K Takatsuki.   

Abstract

Eighteen autopsy cases of adult T-cell leukemia (ATL) were investigated clinicopathologically. Thirteen of the patients had hypercalcemia during their clinical course. Nine of the thirteen had a high level of serum calcium at the terminal stage, even after extensive chemotherapy. Microscopic examination of the bone revealed proliferation of osteoclasts and bone resorption in eight patients. No osteoclast proliferation or bone resorption was found in the other nine normocalcemic patients. The infiltration of ATL cells was observed in only two patients--one was hypercalcemic and the other, normocalcemic. The factors affecting the serum calcium level were examined in two hypercalcemic patients. Hypercalcemia could not be accounted for by parathyroid hormone or prostaglandins E levels, which were in the normal range, or by 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, which were low. Our findings are consistent with the mechanism proposed by several investigators, that the malignant T-lymphocytes produced an osteoclast-activating-factor-like substance that caused osteoclast proliferation and hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880656     DOI: 10.1002/1097-0142(19870315)59:6<1187::aid-cncr2820590626>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

2.  Disorders of serum calcium in acquired immunodeficiency syndrome.

Authors:  S A Peter
Journal:  J Natl Med Assoc       Date:  1992-07       Impact factor: 1.798

Review 3.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Primary bone adult T cell lymphoma with multiple skeletal lesions and debilitating painful osteolysis: a case report.

Authors:  H Kato; M Koga; H Kobayashi; H Maki; M Ikemura; M Kurokawa; M Nangaku; N Makita; N Ito
Journal:  Osteoporos Int       Date:  2020-10-31       Impact factor: 4.507

5.  Production of tumor necrosis factors by human T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

6.  Expression of a protein involved in bone resorption, Dkk1, is activated by HTLV-1 bZIP factor through its activation domain.

Authors:  Nicholas Polakowski; Heather Gregory; Jean-Michel Mesnard; Isabelle Lemasson
Journal:  Retrovirology       Date:  2010-07-23       Impact factor: 4.602

7.  Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors:  Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Primary adult T-cell leukemia/lymphoma of bone.

Authors:  Tomoko Hara; Shingo Wakatsuki; Shuji Ozaki; Masahiro Abe; Masaaki Kosaka
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

9.  Expression of tumor invasion factors determines systemic engraftment and induction of humoral hypercalcemia in a mouse model of adult T-cell leukemia.

Authors:  C Parrula; B Zimmerman; P Nadella; S Shu; T Rosol; S Fernandez; M Lairmore; S Niewiesk
Journal:  Vet Pathol       Date:  2009-05-09       Impact factor: 2.221

10.  Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation.

Authors:  Marcia Bellon; Nga Ling Ko; Min-Jung Lee; Yuan Yao; Thomas A Waldmann; Jane B Trepel; Christophe Nicot
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.